Skip to main content

Terns Pharmaceuticals, Inc.

corporate_fare Company Profile

Terns Pharmaceuticals, Inc.

TERN·NASDAQ·Healthcare·CIK 0001831363

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule drug candidates for cancer and obesity. The company is developing TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in a Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a type of bone marrow cancer. Terns Pharmaceuticals also develops TERN-501, a thyroid hormone receptor beta agonist designed for improved metabolic stability and liver distribution. TERN-501 is in a Phase IIa clinical trial for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the company is working on the TERN-801 series, which are small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators intended for obesity. Terns Pharmaceuticals, Inc. was incorporated in 2016 and its headquarters are located in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 15 items for TERN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-05, rated 10/10. Across its 15 most recent items scored 7 or higher, the top rating is 10/10, with 12 rated 8 or above. Recent SEC coverage for TERN spans 8-K, SC TO-T/A, 10-K/A, SC 14D9/A.

Recent high-impact activity:

  • Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist
  • Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist from Nasdaq
  • Merck Finalizes Acquisition of Terns Pharmaceuticals
  • Terns Pharmaceuticals Amends 10-K to Detail Executive Compensation and Equity Plans Amidst Tender Offer
  • FDA Grants Breakthrough Status to TERN-701 for Ph+ CML, Accelerating Development

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$96.21M
Diluted EPS
-$1.03
Op. Cash Flow
-$82.18M
Free Cash Flow
-$82.18M
Operating Income
-$110.12M
Cash & Equivalents
$524.75M
Debt / Equity
0.00×
Shares Outstanding
112.32M sh
Source: 10-K · filed 2026-04-27 · accession 0001193125-26-182140
Browse all tickers starting with T →

No longer listed

TERN (Terns Pharmaceuticals, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. Terns Pharmaceuticals, Inc was acquired by Merck & Co., Inc (MRK). The filings and coverage below remain available as an archive.

feed TERN - Latest Insights

TERN
May 05, 2026, 9:21 AM EDT
Filing Type: 8-K
Importance Score:
10
Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist
Sentiment: Neutral
View Wiseek Article
TERN
May 05, 2026, 8:52 AM EDT
Filing Type: SC TO-T/A
Importance Score:
10
Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist from Nasdaq
Sentiment: Positive
View Wiseek Article
TERN
May 05, 2026, 8:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Merck Finalizes Acquisition of Terns Pharmaceuticals
Sentiment: Positive
View Wiseek Article
TERN
Apr 27, 2026, 4:18 PM EDT
Filing Type: 10-K/A
Importance Score:
7
Terns Pharmaceuticals Amends 10-K to Detail Executive Compensation and Equity Plans Amidst Tender Offer
Sentiment: Neutral
View Wiseek Article
TERN
Apr 27, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
FDA Grants Breakthrough Status to TERN-701 for Ph+ CML, Accelerating Development
Sentiment: Positive
View Wiseek Article
TERN
Apr 27, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
TERN-701 Receives FDA Breakthrough Therapy Designation for CML, Accelerating Development Amidst Merck Acquisition
Sentiment: Positive
View Wiseek Article
TERN
Apr 24, 2026, 8:11 AM EDT
Filing Type: SC 14D9/A
Importance Score:
8
Merck Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires; New Stockholder Lawsuit Disclosed
Sentiment: Neutral
View Wiseek Article
TERN
Apr 24, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Merck Acquisition of Terns Pharmaceuticals Advances with HSR Waiting Period Expiration
Sentiment: Neutral
View Wiseek Article
TERN
Apr 07, 2026, 7:44 AM EDT
Filing Type: SC 14D9
Importance Score:
9
Terns Board Unanimously Recommends Shareholders Accept Merck's $53.00/Share Cash Tender Offer
Sentiment: Positive
View Wiseek Article
TERN
Apr 07, 2026, 7:00 AM EDT
Filing Type: SC TO-T
Importance Score:
10
Merck Commences Tender Offer to Acquire Terns Pharmaceuticals for $53.00 Per Share in Cash
Sentiment: Positive
View Wiseek Article
TERN
Mar 25, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
10
Merck to Acquire Terns Pharmaceuticals for $53.00/Share, Valuing Company at $6.7 Billion
Sentiment: Positive
View Wiseek Article
TERN
Mar 25, 2026, 6:48 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Merck to Acquire Terns Pharmaceuticals, Bolstering Hematology Pipeline with CML Drug TERN-701
Sentiment: Positive
View Wiseek Article
TERN
Jan 22, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Terns Pharmaceuticals Secures Exclusive Worldwide Rights to TERN-701 Patents from Hansoh
Sentiment: Positive
View Wiseek Article
TERN
Jan 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
Terns Pharmaceuticals Secures $1B Cash Runway into 2031, Advances Lead Oncology Drug TERN-701 with Fast Track and Positive Data
Sentiment: Positive
View Wiseek Article
TERN
Jan 06, 2026, 8:26 PM EST
Filing Type: 4
Importance Score:
7
Terns Pharmaceuticals CEO Exercises Options and Increases Stake by Over $3.2M Net
Sentiment: Positive
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets